Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

Disclosures The author is a clinical investigator, a paid consultant, and owns common stock (individual investment) in Novo Nordisk, Inc. He is also a paid consultant and clinical investigator for Lilly, Sanofi-Aventis, Pfizer, Merck, Medtronic, Inc., and Johnson and Johnson. The author is also a paid consultant, clinical investigator and owns common stock (individual investment) in Amylin Pharmaceuticals.